Wayne Koch is a national and international leader in head and neck oncologic surgery, caring for patients with cancers of the oral cavity, salivary gland, larynx, hypopharynx, oropharynx and thyroid. Among Dr. Koch's landmark publications are studies demonstrating how key molecular events such as p53 mutation and human papillomavirus (HPV) contribute to the development of head and neck cancer. His peer-reviewed publications include six articles in the New England Journal of Medicine. Dr. Koch is also involved in humanitarian outreach focused on training surgeons in several African nations. He has served as president of the American Head and Neck Society, the national organization of head and neck cancer surgeons in the USA. Dr. Koch is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Human Papillomavirus Infection, Laryngectomy, and Gastrostomy.

Vassiliki Saloura is an Otolaryngologist and an Oncologist in Baltimore, Maryland. Dr. Saloura is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Wolf-Hirschhorn Syndrome, Glioma, and Tongue Cancer.

Maie John is an Otolaryngologist in Baltimore, Maryland. Dr. John is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Melanoma, Glossectomy, and Gastrostomy.

Ranee Mehra is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mehra is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Tongue Cancer, and Glossectomy. Dr. Mehra is currently accepting new patients.

David Sidransky is an Oncologist and an Otolaryngologist in Baltimore, Maryland. Dr. Sidransky is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Polymorphous Low Grade Adenocarcinoma.

Dr. Harry Quon is an associate professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also holds appointments in oncology and in otolaryngology - head and neck surgery. His area of clinical expertise is radiation treatment for head and neck cancers. He serves as the co-director of the Johns Hopkins Head and Neck Cancer Multidisciplinary Clinic. Dr. Quon received his M.D. from the University of Toronto Institute of Medical Science. He completed his residency at the Princess Margaret Hospital in Ontario and performed a fellowship in radiation oncology at the Princess Margaret Hospital and the Beth Israel Medical Center. Make A Gift. Dr. Quon is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Laryngeal Cancer, Throat Cancer, Dry Mouth, Gastrostomy, and Prostatectomy.

Christine Gourin, M.D. M.P.H., is a head and neck surgical oncologist and palliative medicine specialist who treats patients with head and neck tumors, including tumors of the skin, melanoma, oral cavity, larynx, oropharynx, neck, salivary glands, sinuses, and skull base. Dr. Gourin received her medical degree from the State University of New York-Health Science Center at Brooklyn/Downstate Medical Center. Dr. Gourin trained in General Surgery and Otolaryngology-Head and Neck Surgery at the University of Vermont, followed by a fellowship in Advanced Head and Neck Oncologic Surgery at the University of Pittsburgh and a fellowship in Hospice and Palliative Medicine at Johns Hopkins University. She has authored over 200 peer-reviewed journal articles, 24 book chapters and two books: Medical and Surgical Management of Thyroid and Parathyroid Diseases and The Johns Hopkins Patient Guide to Head and Neck Cancer. She is on the Editorial Board of The Laryngoscope and is a reviewer for numerous other head and neck surgery journals. Dr. Gourin is a nationally and internationally recognized expert in quality of care and outcomes with a lifelong interest in improved symptom management, communication, access to high-quality affordable care, and palliative medicine in head and neck cancer. She has an active head and neck surgical oncology practice and has been named to America’s Top Physicians and Best Doctors in America annually since 2005. She is the Director of the Johns Hopkins Head and Neck Cancer Supportive Care Clinic. Dr. Gourin is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Tongue Cancer, Laryngectomy, and Gastrostomy.

Head and neck surgeon David Eisele specializes in surgery for malignant and benign tumors of the head and neck, with a focus on salivary gland neoplasms and disorders of the salivary glands that can be treated surgically. He is an expert in minimally invasive surgical approaches, including sialendoscopy. Salivary gland neoplasms and disorders are also the focus of Dr. Eisele’s research. He has published more than 300 research papers and edited multiple books related to head and neck surgery. Dr. Eisele earned a medical degree from Cornell University Medical College and completed residency training in general surgery and in otolaryngology–head and neck surgery at the University of Washington. From 2012 to 2025, he served as director of the Department of Otolaryngology–Head and Neck Surgery at the Johns Hopkins University School of Medicine. Dr. Eisele is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Salivary Duct Stones, Salivary Gland Tumors, Throat Cancer, Laryngectomy, and Gastrostomy.

Dr. Carole Fakhry is a head and neck surgical oncologist at Johns Hopkins and treats the breadth of patients with head and neck cancers, including cancers of the tonsils, base of tongue, mouth, larynx, thyroid, salivary gland (parotid, submandibular gland) and skin cancers among others. She is the Chief of the Division of Head and Neck Surgery and Director of the Head and Neck Cancer Center. She also serves as director of the head and neck group in the Bloomberg~Kimmel Institute for Cancer Immunotherapy and the head and neck surgical oncology fellowship. She is the associate editor for Oral Oncology and serves on several editorial boards. After an undergraduate degree at Stanford University, she completed medical school, residency in otolaryngology head and neck surgery, and a fellowship in head and neck surgical oncology at Johns Hopkins. She has also received a master’s in public health from the Johns Hopkins Bloomberg School of Public Health. She is presently a professor in the Johns Hopkins Department of Otolaryngology-Head and Neck Surgery, Oncology, and Johns Hopkins Bloomberg School of Public Health Department of Epidemiology. Her research interest focuses on the role of human papillomavirus (HPV) in head and neck squamous cell cancer. She has demonstrated that the presence of HPV confers a prognostic advantage to individuals with oropharyngeal cancer and that HPV is associated with unique clinical characteristics. In addition to the clinical implications of HPV in head and neck cancer, she is co-principal investigator of a large study to understand screening individuals at “high risk” of malignancy and evaluating imaging modalities to improve diagnostics and early detection of HPV- related head and neck cancer. Dr. Fakhry is rated as an Elite provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Human Papillomavirus Infection, Head and Neck Squamous Cell Carcinoma (HNSCC), Tongue Cancer, Laryngectomy, and Gastrostomy.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Throat Cancer, Gastrostomy, and Adenoidectomy.

Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. He received his medical degree in 2005 from the Mount Sinai School of Medicine in New York City, where he graduated with distinction in research. He completed his internship and residency in Internal Medicine at The Johns Hopkins Hospital, and completed a Medical Oncology fellowship at the Johns Hopkins Kimmel Cancer Center. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Dr. Lipson’s publications include the first reports of organ transplant recipients treated with immune checkpoint inhibitors for advanced cancer, and the first description of kidney retransplantation performed after immunotherapy–related organ rejection. Based on his published work, Dr. Lipson initiated a clinical trial testing a novel combination of immune-based therapies for kidney transplant recipients with advanced selected cancers. Results from this trial - the first of its kind - were reported in 2022 at an international oncology meeting. Dr. Lipson is a leader in the clinical development of relatlimab, an antibody blocking the LAG-3 immune checkpoint. He leads a phase 2 trial testing combination immune checkpoint inhibitor therapy—including anti-LAG-3—for patients with advanced basal cell carcinoma. In June 2021, Dr. Lipson presented findings from the first phase 3 study establishing the LAG-3 pathway as the third immune checkpoint pathway in history, after CTLA-4 and PD-1, for which blockade has clinical benefit. This trial supported the FDA's approval of a new therapy for patients with advanced melanoma. In addition to his research activities, Dr. Lipson is an educator in the field of cancer immunotherapy. Many of his lectures focus on the management of immune-mediated drug toxicities associated with novel cancer drugs. Dr. Lipson conducts regular clinical practices in Baltimore, Maryland and at Sibley Memorial Hospital in Washington, D.C. as part of the multidisciplinary Melanoma Program at Johns Hopkins. Dr. Lipson is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Pancreaticoduodenectomy.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Dr. Won Jin Ho is a physician-scientist at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins who focuses on cancer immunology and tumor microenvironment research. Dr. Ho received his BS and MS in Biomedical Engineering from University of California, Los Angeles, and his MD from Wayne State University School of Medicine. Dr. Ho completed a research track internal medicine residency as an NIH F32 postdoctoral fellow at Case Western Reserve University and subsequently completed a medical oncology fellowship at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as the recipient of ASCO Young Investigator Award and AACR Immuno-Oncology Fellowship. Dr. Ho's overarching research interest is to develop novel immunotherapeutic strategies even against immune-resistant cancers by first understanding the immune responses to current therapeutics. Dr. Ho focuses on determining the systemic and in situ changes by leveraging cutting-edge technologies. With his expertise in mass cytometry, Dr. Ho is co-leading many of the systemic and spatial immune profiling efforts at Johns Hopkins. Dr. Ho also is developing novel small-molecule cancer therapeutics and methodologies for translational discovery. Dr. Ho is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Fibrolamellar Carcinoma, Liver Cancer, and Hepato-Pancreato-Biliary Surgery.

Dr. Grant Anhalt is a professor of dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include autoimmune skin diseases and dermatoimmunology. Dr. Anhalt serves as the director of the Dermatoimmunology Laboratory at the Johns Hopkins School of Medicine. He received his undergraduate degree and his M.D. from the University of Manitoba. He completed a residency in internal medicine at the Health Sciences Center in Winnipeg, Canada and a residency in dermatology at the University of Michigan. He performed a fellowship in immunodermatology at the University of Michigan Medical Center. Dr. Anhalt joined the Johns Hopkins faculty in 1982. He was interim chair of the Department of Dermatology from 1996 to 2001. His research interests include autoimmunity, bullous skin diseases and pemphigus and pemphigoid. Dr. Anhalt serves on the medical advisory board for the International Pemphigus & Pemphigoid Foundation. He has been recognized as a top doctor in the Washington Post Magazine, Baltimore Magazine and Castle Connolly Guide. He is a member of several professional organizations, including the American Academy of Dermatology, American Dermatologic Association and American Society for Clinical Investigation. CV http://www.hopkinsmedicine.org/dermatology/our_experts/CV/Anhalt_CV_2014.docx. Dr. Anhalt is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pemphigus Vulgaris, Pemphigus, Pemphigus Foliaceus, and Bullous Pemphigoid.

Dr. Kofi Derek Owusu Boahene is a professor of otolaryngology-head and neck surgery and dermatology at the Johns Hopkins University School of Medicine. He is the Director of the Division of Facial Plastics and Reconstructive Surgery and the director for the facial plastics fellowship training program. His practice encompasses the entire spectrum of facial plastic and reconstructive surgery including cosmetic and reconstructive aspects. Dr. Boahene is a leading expert in facial paralysis surgery and facial nerve injuries and has pioneered innovative treatment protocols and surgical techniques in facial reanimation. He is the director of the Johns Hopkins Facial Nerve center dedicated to restoring facial balance, symmetry and animation to those who have suffered from facial paralysis and facial nerve disorders. As an expert microsurgeon, Dr. Boahene routinely performs some of the most complex facial reconstruction procedures on the face including rebuilding of an entire nose, lip, jaw and facial defects resulting from cancer treatment, traumatic injuries or as a result of birth defects. He uses cutting edge 3-D technology, image-guided technology and tissue transplanted from other parts of the body to restore or replace missing tissues. He is a key member of the Johns Hopkins facial transplant program. His cosmetic experience is broad and draws from patients across the globe. He routinely performs rhinoplasties, eyelid surgery, face lifts and other facial enhancing procedures. As a skull base surgeon, Dr. Boahene has pioneered minimally invasive techniques for removal of skull base and brain tumors, repairing CSF leaks and has authored a major textbook on this subject. Dr. Boahene received his undergraduate degree from the University of Central Arkansas. He graduated summa cum laude from Meharry Medical College in Nashville, Tennessee, completed a five-year surgical residency training program in otolaryngology-head and neck surgery at the Mayo Clinic in Rochester, Minnesota, and received fellowship training in facial plastic and reconstructive surgery at the University of Minnesota. As the recipient of the prestigious Mayo Brothers Distinguished Fellowship Award, Dr. Boahene was awarded additional craniofacial surgery training in Adelaide, Australia. He also received the Jack R. Anderson Prize for Scholastic Excellence for attaining the highest score nationally on the American Academy of Facial Plastic and Reconstructive Surgery certification exam. Dr. Boahene serves as on the Board of Governors or the American Academy Facial Plastic and Reconstructive Surgery. He is a member of several professional organizations, including the American Academy of Facial Plastic and Reconstructive Surgery and the American Academy of Otolaryngology-Head and Neck Surgery. In 1993, Dr. Kofi Boahene received the Alpha Omega Alpha Medical. Dr. Boahene is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Facial Paralysis, Bell's Palsy, Recurrent Peripheral Facial Palsy, Septoplasty, and Gastrostomy.

Dr. Damon S. Cooney is an associate professor of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine. Dr. Cooney performs all types of general plastic surgery but specializes in microvascular reconstruction (free flaps). A particular focus of his clinical practice is improving the functional and aesthetic results of head and neck reconstruction. He completed additional fellowship training at the University of Pittsburgh to become an expert in microsurgical techniques for reconstructing the extremities, trunk, breast, and head and neck following traumatic and/or oncological defects. Dr. Cooney earned a Ph.D. from Ohio State University Department of Molecular, Cellular and Development Biology. Dr. Cooney’s clinical and basic research focus is composite tissue allotransplantation (CTA). He is a member of the Composite Tissue Allotransplantation team at Johns Hopkins and helps conduct human hand and face transplantation trials. His laboratory work includes engineering human tissues for reconstructive purposes, nerve regeneration, microsurgical education and inducing tolerance in order to reduce or eliminate the need for systemic immunosuppression in transplantation patients. Dr. Cooney has published numerous peer-reviewed articles and book chapters in addition to being a reviewer for plastic surgery journals. He is a founding member of the American Society for Reconstructive Transplantation. Dr. Cooney is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Keloids, Hidradenitis Suppurativa, Squamous Cell Skin Carcinoma, Osteotomy, and Abdominal Wall Surgery.

Dr. Mark Yarchoan is a physician–scientist based in Baltimore who specializes in the treatment and study of gastrointestinal cancers, with a particular focus on liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). He received his undergraduate degree from Amherst College and his medical degree from the Perelman School of Medicine at the University of Pennsylvania. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, followed by a fellowship in medical oncology at the Johns Hopkins University School of Medicine, where he joined the faculty in 2018. Dr. Yarchoan leads a research laboratory dedicated to developing novel immunotherapies for liver cancers. His translational research program integrates analyses of clinical trial biospecimens with preclinical modeling to identify and overcome barriers to effective antitumor immunity. A major focus of his work is the development of therapeutic cancer vaccines for hepatobiliary malignancies. He serves as Principal Investigator on multiple clinical trials for hepatobiliary cancers, contributes to international guideline committees for liver cancer, and is a member of the Johns Hopkins Graduate Training Programs in Cellular and Molecular Medicine and Immunology. Dr. Yarchoan’s contributions have been recognized with numerous honors, including the ASCO Young Investigator Award, the Conquer Cancer Foundation Career Development Award, the Mark R. Clements Award from the Cholangiocarcinoma Foundation, and the Blue Faery Award for Excellence in Liver Cancer Research. Dr. Yarchoan is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy.

Chad Gordon is a Plastic Surgeon in Baltimore, Maryland. Dr. Gordon is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Neurofibromatosis, Legius Syndrome, Neurofibromatosis Type 1 (NF1), Osteotomy, and Bone Graft.

Jason Molitoris is a Radiologist and a Radiation Oncologist in Baltimore, Maryland. Dr. Molitoris is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Prostate Cancer, Adult Soft Tissue Sarcoma, Familial Prostate Cancer, Anal Cancer, and Gastrostomy.

William Regine is a Radiation Oncologist in Baltimore, Maryland. Dr. Regine is rated as an Experienced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Pancreatic Cancer, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, and Anal Cancer.